Like pls_老虎社区_美港股上老虎

2021-12-01

Like pls

Is Merck Stock A Buy Or Sell After FDA Advisors Narrowly Endorse Covid Pill?<blockquote>在 FDA 顾问勉强认可 Covid Pill 后，默克股票是买入还是卖出？</blockquote>

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":603062571,"tweetId":"603062571","gmtCreate":1638341257058,"gmtModify":1638341257199,"author":{"id":3569243948486771,"idStr":"3569243948486771","authorId":3569243948486771,"authorIdStr":"3569243948486771","name":"EdInvesting","avatar":"https://static.tigerbbs.com/3f2b5d72aa406299a552424310e264b8","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":32,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"","extraTitle":"","html":"<html><head></head><body>Like pls&nbsp;</body></html>","htmlText":"<html><head></head><body>Like pls&nbsp;</body></html>","text":"Like pls","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/603062571","repostId":1170675098,"repostType":4,"repost":{"id":"1170675098","kind":"news","pubTimestamp":1638340930,"share":"https://www.laohunote.com/m/news/1170675098?lang=zh_CN&edition=full","pubTime":"2021-12-01 14:42","market":"us","language":"en","title":"Is Merck Stock A Buy Or Sell After FDA Advisors Narrowly Endorse Covid Pill?<blockquote>在 FDA 顾问勉强认可 Covid Pill 后，默克股票是买入还是卖出？</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1170675098","media":"Investors","summary":"Food and Drug Administration advisors recommended Merck's (MRK) Covid pill for some patients in late","content":"Food and Drug Administration advisors recommended&nbsp;Merck's (MRK) Covid pill for some patients in late November, but Merck stock remains under pressure.<blockquote>食品药品监督管理局顾问推荐默克(MRK) 的 Covid 药丸于 11 月下旬上市，用于部分患者，但默克股票仍面临压力。</blockquote> The FDA's Antimicrobial Drugs Advisory Committee voted 13-10 on Nov. 30, saying the benefits of the Ridgeback Biotherapeutics-partnered pill outweigh its risks. The pill, dubbed molnupiravir, reduced the risk of hospitalization or death in mild-to-moderate Covid patients with risk factors for severe disease.<blockquote>FDA 抗菌药物咨询委员会于 11 月 30 日以 13 比 10 的投票结果表示，Ridgeback Biotherapeutics 合作的药丸的益处大于其风险。这种名为molnupiravir的药丸降低了有严重疾病风险因素的轻度至中度Covid患者住院或死亡的风险。</blockquote> Next, the full FDA will mull the drug. The agency isn't bound by the committee's guidance. It could also authorize the pill for a broad group, though Merck only has test results so far in unvaccinated patients. Panelists noted there are concerns about molnupiravir in pregnant women.<blockquote>接下来，整个FDA将考虑该药物。该机构不受委员会指导的约束。它还可以授权该药丸用于广泛的人群，尽管默克公司迄今为止只有未接种疫苗的患者的测试结果。小组成员指出，孕妇对莫努匹拉韦存在担忧。</blockquote> Merck is going up against&nbsp;Pfizer(PFE). The companies tested a similar patient group. But Merck's pill reduced the risk of severe outcomes by 30% when patients began treatment within five days of symptoms appearing. Pfizer's two-pill regimen cut the risk by 89% when treating within three days.<blockquote>默克公司反对辉瑞（PFE）。两家公司测试了类似的患者群体。但当患者在症状出现后五天内开始治疗时，默克公司的药丸将严重后果的风险降低了 30%。辉瑞的两片药方案在三天内治疗时将风险降低了89%。</blockquote> Prior to its Pfizer-tied dive, Merck stock was trading at a three-decade high. The company beat third-quarter expectations and offered a bullish 2021 outlook that didn't include the potential impact of the antiviral pill. The pill just gained authorization in the U.K. where it will sell under the name Lagevrio.<blockquote>在辉瑞暴跌之前，默克股价处于三十年来的高点。该公司第三季度的业绩超出了预期，并提供了乐观的 2021 年前景，其中不包括抗病毒药物的潜在影响。该药丸刚刚在英国获得授权，将以 Lagevrio 的名称销售。</blockquote> Merck already has a deal with the U.S. government for 1.7 million courses of molnupiravir. Further, it has agreed to supply the U.K. with 480,000 courses of the drug. It plans to make 10 million courses in 2021 and at least 20 million in 2022.<blockquote>默克公司已经与美国政府就 170 万个疗程的莫努匹拉韦达成协议。此外，它已同意向英国供应 48 万个疗程的该药物。它计划在2021年制作1000万门课程，在2022年至少制作2000万门课程。</blockquote> So, all in all, is Merck stock a buy or a sell right now?<blockquote>那么，总而言之，默克股票现在是买入还是卖出？</blockquote> Merck Stock Fundamentals: Sales Top<blockquote>默克股票基本面：销售榜首</blockquote> During the third quarter, adjusted earnings climbed 28% to $1.75 per share and sales soared 20% to $13.15 billion. Both metrics beat forecasts.<blockquote>第三季度，调整后收益攀升 28%，达到每股 1.75 美元，销售额飙升 20%，达到 131.5 亿美元。这两项指标都超出了预期。</blockquote> Merck also provided guidance following its&nbsp;Organon(OGN) spinoff. The pharma company boosted its full-year outlook to adjusted profit of $5.65-$5.70 per share on $47.4 billion to $47.9 billion in sales. Both measures topped expectations. And they don't include the potential for molnupiravir to gain authorizations in the U.S. or Europe.<blockquote>默克公司还提供了指导器官（OGN）衍生产品。这家制药公司将全年预期上调至调整后每股利润 5.65-5.70 美元，销售额从 474 亿美元上调至 479 亿美元。这两项指标都超出了预期。它们不包括莫努匹拉韦在美国或欧洲获得授权的潜力。</blockquote> The company's biggest single drug remains cancer treatment Keytruda. Keytruda accounted for more than a third of total third-quarter sales. Keytruda sales increased 22% to $4.53 billion. Sales of its human papillomavirus vaccine, Gardasil, soared 68% to $1.99 billion.<blockquote>该公司最大的单一药物仍然是癌症治疗药物 Keytruda。Keytruda 占第三季度总销售额的三分之一以上。Keytruda 销售额增长 22%，达到 45.3 亿美元。其人乳头瘤病毒疫苗 Gardasil 的销售额飙升 68%，达到 19.9 亿美元。</blockquote> But revenue from diabetes med Januvia fell 1% to $1.34 billion. And Merck reported a 26% decline for its pneumonia vaccine, Pneumovax 23, as Covid vaccines took priority in the U.S.<blockquote>但糖尿病药物 Januvia 的收入下降了 1%，至 13.4 亿美元。默克公司报告称，随着新冠疫苗在美国获得优先权，其肺炎疫苗 Pneumovax 23 的销量下降了 26%。</blockquote> Overall, third-quarter metrics were in line withCAN SLIM rules for investing,which advise investors to look for companies with recent quarterly growth of 20%-25%, or better.<blockquote>总体而言，第三季度的指标符合 CAN SLIM 投资规则，该规则建议投资者寻找最近季度增长率为 20%-25% 或更好的公司。</blockquote> In the current quarter, analysts polled by FactSet expect Merck to earn $1.54 per share on $13.2 billion in sales. On a year-over-year basis, earnings would surge almost 22% and sales would rise north of 5%.<blockquote>FactSet 调查的分析师预计，本季度默克公司的销售额为 132 亿美元，每股收益为 1.54 美元。按年计算，盈利将激增近 22%，销售额将增长 5% 以上。</blockquote> What Do Annual Metrics Say About Merck?<blockquote>年度指标说明了默克公司的什么？</blockquote> As of the close on Nov. 30, Merck stock was down more than 4% for the year. Shares recently hit at least a three-decade high, but have since tumbled.<blockquote>截至11月30日收盘，默克股价年内下跌超过4%。股价最近触及至少三十年来的高点，但此后一直暴跌。</blockquote> Last year, Merck's sales grew 2.5% to $47.99 billion. That decelerated from 11% growth in 2019.<blockquote>去年，默克公司的销售额增长了 2.5%，达到 479.9 亿美元。这比 2019 年 11% 的增长率有所放缓。</blockquote> For 2021, analysts expect sales to rise a fraction to $48.49 billion. Income is projected to inch 2.7% higher to $5.81 a share. That follows 14% growth in 2020.<blockquote>分析师预计 2021 年销售额将小幅增长至 484.9 亿美元。收入预计将增长 2.7%，达到每股 5.81 美元。此前，2020 年增长了 14%。</blockquote> The stock ranks fifth by&nbsp;Composite Rating&nbsp;in the industry group of pharma companies. The 33-company Medical-Ethical Drugs group ranks a middling No. 95 out of 197 groups tracked by Investor's Business Daily.<blockquote>该股在制药公司行业组中的综合评级排名第五。在《投资者商业日报》追踪的 197 个集团中，由 33 家公司组成的医疗伦理药物集团排名第 95 位。</blockquote> Merck Stock News: Merck Grabs Covid Deal<blockquote>默克股票新闻：默克获得新冠交易</blockquote> Merck's molnupiravir is now authorized in the U.K. Merck will supply the U.K. with 480,000 courses of the drug, now selling under the brand name Lagevrio. Now that the FDA's advisors have recommended molnupiravir, the full agency will consider the drug.<blockquote>默克公司的莫努匹拉韦现已在英国获得授权。默克公司将向英国供应 48 万个疗程的该药物，目前以 Lagevrio 品牌销售。现在FDA的顾问已经推荐了molnupiravir，整个机构将考虑这种药物。</blockquote> The U.S. deal for 1.7 million courses is worth $1.2 billion to Merck. If successful, molnupiravir could hit the U.S. market before the end of the year.<blockquote>170万门课程的美国交易对默克公司来说价值12亿美元。如果成功，molnupiravir可能会在今年年底前登陆美国市场。</blockquote> In addition to Merck and Pfizer,Atea Pharmaceuticals(AVIR) and&nbsp;Enanta Pharmaceuticals(ENTA) working on oral Covid drugs.Roche(RHHBY) recently pulled out of its deal with Atea for the Covid antiviral.<blockquote>除了默沙东和辉瑞，Atea制药（阿韦）和Enanta制药（ENTA）研究口服Covid药物。罗氏(RHHBY) 最近退出了与 Atea 就 Covid 抗病毒药物达成的协议。</blockquote> Analysts say the pills could offer an easier route for non-hospitalized treatment of Covid than antibody drugs from&nbsp;Regeneron Pharmaceuticals(REGN),Eli Lilly(LLY) and&nbsp;Vir Biotechnology(VIR). Antibody drugs must be given by health care professionals.<blockquote>分析人士表示，与抗体药物相比，这些药丸可以为新冠病毒的非住院治疗提供更简单的途径再生元制药（雨），礼来（LLY）和生物技术（来源）。抗体药物必须由医疗保健专业人员给予。</blockquote> But there is some concern that the way molnupiravir works could introduce mutations into the DNA of an unborn baby. So, FDA advisors waffled on whether to recommend its use for pregnant women.<blockquote>但有人担心molnupiravir的工作方式可能会将突变引入未出生婴儿的DNA。因此，FDA顾问在是否建议孕妇使用它的问题上犹豫不决。</blockquote> Further, Merck and&nbsp;Gilead Sciences(GILD) began a Phase 2 study testing a combination of their oral HIV treatments. The drugs, known as islatravir and lenacapavir can stay in the body for a long time. This means patients can take medicine less frequently. In this case, the companies are testing a weekly dosing regimen.<blockquote>此外，默克和吉利德科学（GILD）开始了一项2期研究，测试他们口服HIV治疗的组合。被称为islatravir和lenacapavir的药物可以在体内停留很长时间。这意味着患者可以减少服药的频率。在这种情况下，两家公司正在测试每周给药方案。</blockquote> Merck also recently finished acquiring Acceleron.<blockquote>默克公司最近还完成了对 Acceleron 的收购。</blockquote> In early March, President Joe Biden announced Merck would help&nbsp;Johnson &amp; Johnson(JNJ) produce its Covid vaccine. Merck will receive $268.8 million from the Biomedical Advanced Research and Development Authority to help expand facility space to do so.<blockquote>三月初，乔·拜登总统宣布默克将提供帮助强生公司（JNJ）生产新冠疫苗。默克将从生物医学高级研究与发展局获得 2.688 亿美元，以帮助扩大设施空间。</blockquote> Is Merck Stock A Buy Now?<blockquote>默克股票现在值得买入吗？</blockquote> Based on CAN SLIM rules for investing, no, Merck stock is not a buy right now. Shares have round-tripped their earlier breakout and have triggered several sell signals.<blockquote>根据 CAN SLIM 投资规则，不，默克股票现在不值得购买。股价已经扭转了早些时候的突破，并引发了几个卖出信号。</blockquote> There are further caveats. Both Merck's sales and earnings met CAN SLIM guidelines in the third quarter. Sales aren't expected to meet that mark in the current quarter.<blockquote>还有进一步的警告。默克公司第三季度的销售额和盈利均符合 CAN SLIM 指导方针。预计本季度销售额不会达到这一里程碑。</blockquote> Still, big stocks like Merck can add gains without hitting massive growth streaks.<blockquote>尽管如此，像默克这样的大盘股可以在不实现大幅增长的情况下增加涨幅。</blockquote>","source":"lsy1638341066627","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Merck Stock A Buy Or Sell After FDA Advisors Narrowly Endorse Covid Pill?<blockquote>在 FDA 顾问勉强认可 Covid Pill 后，默克股票是买入还是卖出？</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Merck Stock A Buy Or Sell After FDA Advisors Narrowly Endorse Covid Pill?<blockquote>在 FDA 顾问勉强认可 Covid Pill 后，默克股票是买入还是卖出？</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nInvestors2021-12-01 14:42\n\n</h4>\n</header>\n<article>\nFood and Drug Administration advisors recommended&nbsp;Merck's (MRK) Covid pill for some patients in late November, but Merck stock remains under pressure.<blockquote>食品药品监督管理局顾问推荐默克(MRK) 的 Covid 药丸于 11 月下旬上市，用于部分患者，但默克股票仍面临压力。</blockquote> The FDA's Antimicrobial Drugs Advisory Committee voted 13-10 on Nov. 30, saying the benefits of the Ridgeback Biotherapeutics-partnered pill outweigh its risks. The pill, dubbed molnupiravir, reduced the risk of hospitalization or death in mild-to-moderate Covid patients with risk factors for severe disease.<blockquote>FDA 抗菌药物咨询委员会于 11 月 30 日以 13 比 10 的投票结果表示，Ridgeback Biotherapeutics 合作的药丸的益处大于其风险。这种名为molnupiravir的药丸降低了有严重疾病风险因素的轻度至中度Covid患者住院或死亡的风险。</blockquote> Next, the full FDA will mull the drug. The agency isn't bound by the committee's guidance. It could also authorize the pill for a broad group, though Merck only has test results so far in unvaccinated patients. Panelists noted there are concerns about molnupiravir in pregnant women.<blockquote>接下来，整个FDA将考虑该药物。该机构不受委员会指导的约束。它还可以授权该药丸用于广泛的人群，尽管默克公司迄今为止只有未接种疫苗的患者的测试结果。小组成员指出，孕妇对莫努匹拉韦存在担忧。</blockquote> Merck is going up against&nbsp;Pfizer(PFE). The companies tested a similar patient group. But Merck's pill reduced the risk of severe outcomes by 30% when patients began treatment within five days of symptoms appearing. Pfizer's two-pill regimen cut the risk by 89% when treating within three days.<blockquote>默克公司反对辉瑞（PFE）。两家公司测试了类似的患者群体。但当患者在症状出现后五天内开始治疗时，默克公司的药丸将严重后果的风险降低了 30%。辉瑞的两片药方案在三天内治疗时将风险降低了89%。</blockquote> Prior to its Pfizer-tied dive, Merck stock was trading at a three-decade high. The company beat third-quarter expectations and offered a bullish 2021 outlook that didn't include the potential impact of the antiviral pill. The pill just gained authorization in the U.K. where it will sell under the name Lagevrio.<blockquote>在辉瑞暴跌之前，默克股价处于三十年来的高点。该公司第三季度的业绩超出了预期，并提供了乐观的 2021 年前景，其中不包括抗病毒药物的潜在影响。该药丸刚刚在英国获得授权，将以 Lagevrio 的名称销售。</blockquote> Merck already has a deal with the U.S. government for 1.7 million courses of molnupiravir. Further, it has agreed to supply the U.K. with 480,000 courses of the drug. It plans to make 10 million courses in 2021 and at least 20 million in 2022.<blockquote>默克公司已经与美国政府就 170 万个疗程的莫努匹拉韦达成协议。此外，它已同意向英国供应 48 万个疗程的该药物。它计划在2021年制作1000万门课程，在2022年至少制作2000万门课程。</blockquote> So, all in all, is Merck stock a buy or a sell right now?<blockquote>那么，总而言之，默克股票现在是买入还是卖出？</blockquote> Merck Stock Fundamentals: Sales Top<blockquote>默克股票基本面：销售榜首</blockquote> During the third quarter, adjusted earnings climbed 28% to $1.75 per share and sales soared 20% to $13.15 billion. Both metrics beat forecasts.<blockquote>第三季度，调整后收益攀升 28%，达到每股 1.75 美元，销售额飙升 20%，达到 131.5 亿美元。这两项指标都超出了预期。</blockquote> Merck also provided guidance following its&nbsp;Organon(OGN) spinoff. The pharma company boosted its full-year outlook to adjusted profit of $5.65-$5.70 per share on $47.4 billion to $47.9 billion in sales. Both measures topped expectations. And they don't include the potential for molnupiravir to gain authorizations in the U.S. or Europe.<blockquote>默克公司还提供了指导器官（OGN）衍生产品。这家制药公司将全年预期上调至调整后每股利润 5.65-5.70 美元，销售额从 474 亿美元上调至 479 亿美元。这两项指标都超出了预期。它们不包括莫努匹拉韦在美国或欧洲获得授权的潜力。</blockquote> The company's biggest single drug remains cancer treatment Keytruda. Keytruda accounted for more than a third of total third-quarter sales. Keytruda sales increased 22% to $4.53 billion. Sales of its human papillomavirus vaccine, Gardasil, soared 68% to $1.99 billion.<blockquote>该公司最大的单一药物仍然是癌症治疗药物 Keytruda。Keytruda 占第三季度总销售额的三分之一以上。Keytruda 销售额增长 22%，达到 45.3 亿美元。其人乳头瘤病毒疫苗 Gardasil 的销售额飙升 68%，达到 19.9 亿美元。</blockquote> But revenue from diabetes med Januvia fell 1% to $1.34 billion. And Merck reported a 26% decline for its pneumonia vaccine, Pneumovax 23, as Covid vaccines took priority in the U.S.<blockquote>但糖尿病药物 Januvia 的收入下降了 1%，至 13.4 亿美元。默克公司报告称，随着新冠疫苗在美国获得优先权，其肺炎疫苗 Pneumovax 23 的销量下降了 26%。</blockquote> Overall, third-quarter metrics were in line withCAN SLIM rules for investing,which advise investors to look for companies with recent quarterly growth of 20%-25%, or better.<blockquote>总体而言，第三季度的指标符合 CAN SLIM 投资规则，该规则建议投资者寻找最近季度增长率为 20%-25% 或更好的公司。</blockquote> In the current quarter, analysts polled by FactSet expect Merck to earn $1.54 per share on $13.2 billion in sales. On a year-over-year basis, earnings would surge almost 22% and sales would rise north of 5%.<blockquote>FactSet 调查的分析师预计，本季度默克公司的销售额为 132 亿美元，每股收益为 1.54 美元。按年计算，盈利将激增近 22%，销售额将增长 5% 以上。</blockquote> What Do Annual Metrics Say About Merck?<blockquote>年度指标说明了默克公司的什么？</blockquote> As of the close on Nov. 30, Merck stock was down more than 4% for the year. Shares recently hit at least a three-decade high, but have since tumbled.<blockquote>截至11月30日收盘，默克股价年内下跌超过4%。股价最近触及至少三十年来的高点，但此后一直暴跌。</blockquote> Last year, Merck's sales grew 2.5% to $47.99 billion. That decelerated from 11% growth in 2019.<blockquote>去年，默克公司的销售额增长了 2.5%，达到 479.9 亿美元。这比 2019 年 11% 的增长率有所放缓。</blockquote> For 2021, analysts expect sales to rise a fraction to $48.49 billion. Income is projected to inch 2.7% higher to $5.81 a share. That follows 14% growth in 2020.<blockquote>分析师预计 2021 年销售额将小幅增长至 484.9 亿美元。收入预计将增长 2.7%，达到每股 5.81 美元。此前，2020 年增长了 14%。</blockquote> The stock ranks fifth by&nbsp;Composite Rating&nbsp;in the industry group of pharma companies. The 33-company Medical-Ethical Drugs group ranks a middling No. 95 out of 197 groups tracked by Investor's Business Daily.<blockquote>该股在制药公司行业组中的综合评级排名第五。在《投资者商业日报》追踪的 197 个集团中，由 33 家公司组成的医疗伦理药物集团排名第 95 位。</blockquote> Merck Stock News: Merck Grabs Covid Deal<blockquote>默克股票新闻：默克获得新冠交易</blockquote> Merck's molnupiravir is now authorized in the U.K. Merck will supply the U.K. with 480,000 courses of the drug, now selling under the brand name Lagevrio. Now that the FDA's advisors have recommended molnupiravir, the full agency will consider the drug.<blockquote>默克公司的莫努匹拉韦现已在英国获得授权。默克公司将向英国供应 48 万个疗程的该药物，目前以 Lagevrio 品牌销售。现在FDA的顾问已经推荐了molnupiravir，整个机构将考虑这种药物。</blockquote> The U.S. deal for 1.7 million courses is worth $1.2 billion to Merck. If successful, molnupiravir could hit the U.S. market before the end of the year.<blockquote>170万门课程的美国交易对默克公司来说价值12亿美元。如果成功，molnupiravir可能会在今年年底前登陆美国市场。</blockquote> In addition to Merck and Pfizer,Atea Pharmaceuticals(AVIR) and&nbsp;Enanta Pharmaceuticals(ENTA) working on oral Covid drugs.Roche(RHHBY) recently pulled out of its deal with Atea for the Covid antiviral.<blockquote>除了默沙东和辉瑞，Atea制药（阿韦）和Enanta制药（ENTA）研究口服Covid药物。罗氏(RHHBY) 最近退出了与 Atea 就 Covid 抗病毒药物达成的协议。</blockquote> Analysts say the pills could offer an easier route for non-hospitalized treatment of Covid than antibody drugs from&nbsp;Regeneron Pharmaceuticals(REGN),Eli Lilly(LLY) and&nbsp;Vir Biotechnology(VIR). Antibody drugs must be given by health care professionals.<blockquote>分析人士表示，与抗体药物相比，这些药丸可以为新冠病毒的非住院治疗提供更简单的途径再生元制药（雨），礼来（LLY）和生物技术（来源）。抗体药物必须由医疗保健专业人员给予。</blockquote> But there is some concern that the way molnupiravir works could introduce mutations into the DNA of an unborn baby. So, FDA advisors waffled on whether to recommend its use for pregnant women.<blockquote>但有人担心molnupiravir的工作方式可能会将突变引入未出生婴儿的DNA。因此，FDA顾问在是否建议孕妇使用它的问题上犹豫不决。</blockquote> Further, Merck and&nbsp;Gilead Sciences(GILD) began a Phase 2 study testing a combination of their oral HIV treatments. The drugs, known as islatravir and lenacapavir can stay in the body for a long time. This means patients can take medicine less frequently. In this case, the companies are testing a weekly dosing regimen.<blockquote>此外，默克和吉利德科学（GILD）开始了一项2期研究，测试他们口服HIV治疗的组合。被称为islatravir和lenacapavir的药物可以在体内停留很长时间。这意味着患者可以减少服药的频率。在这种情况下，两家公司正在测试每周给药方案。</blockquote> Merck also recently finished acquiring Acceleron.<blockquote>默克公司最近还完成了对 Acceleron 的收购。</blockquote> In early March, President Joe Biden announced Merck would help&nbsp;Johnson &amp; Johnson(JNJ) produce its Covid vaccine. Merck will receive $268.8 million from the Biomedical Advanced Research and Development Authority to help expand facility space to do so.<blockquote>三月初，乔·拜登总统宣布默克将提供帮助强生公司（JNJ）生产新冠疫苗。默克将从生物医学高级研究与发展局获得 2.688 亿美元，以帮助扩大设施空间。</blockquote> Is Merck Stock A Buy Now?<blockquote>默克股票现在值得买入吗？</blockquote> Based on CAN SLIM rules for investing, no, Merck stock is not a buy right now. Shares have round-tripped their earlier breakout and have triggered several sell signals.<blockquote>根据 CAN SLIM 投资规则，不，默克股票现在不值得购买。股价已经扭转了早些时候的突破，并引发了几个卖出信号。</blockquote> There are further caveats. Both Merck's sales and earnings met CAN SLIM guidelines in the third quarter. Sales aren't expected to meet that mark in the current quarter.<blockquote>还有进一步的警告。默克公司第三季度的销售额和盈利均符合 CAN SLIM 指导方针。预计本季度销售额不会达到这一里程碑。</blockquote> Still, big stocks like Merck can add gains without hitting massive growth streaks.<blockquote>尽管如此，像默克这样的大盘股可以在不实现大幅增长的情况下增加涨幅。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.investors.com/news/technology/merck-stock-buy-now/\">Investors</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东"},"source_url":"https://www.investors.com/news/technology/merck-stock-buy-now/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1170675098","content_text":"Food and Drug Administration advisors recommended Merck's (MRK) Covid pill for some patients in late November, but Merck stock remains under pressure.\nThe FDA's Antimicrobial Drugs Advisory Committee voted 13-10 on Nov. 30, saying the benefits of the Ridgeback Biotherapeutics-partnered pill outweigh its risks. The pill, dubbed molnupiravir, reduced the risk of hospitalization or death in mild-to-moderate Covid patients with risk factors for severe disease.\nNext, the full FDA will mull the drug. The agency isn't bound by the committee's guidance. It could also authorize the pill for a broad group, though Merck only has test results so far in unvaccinated patients. Panelists noted there are concerns about molnupiravir in pregnant women.\nMerck is going up against Pfizer(PFE). The companies tested a similar patient group. But Merck's pill reduced the risk of severe outcomes by 30% when patients began treatment within five days of symptoms appearing. Pfizer's two-pill regimen cut the risk by 89% when treating within three days.\nPrior to its Pfizer-tied dive, Merck stock was trading at a three-decade high. The company beat third-quarter expectations and offered a bullish 2021 outlook that didn't include the potential impact of the antiviral pill. The pill just gained authorization in the U.K. where it will sell under the name Lagevrio.\nMerck already has a deal with the U.S. government for 1.7 million courses of molnupiravir. Further, it has agreed to supply the U.K. with 480,000 courses of the drug. It plans to make 10 million courses in 2021 and at least 20 million in 2022.\nSo, all in all, is Merck stock a buy or a sell right now?\nMerck Stock Fundamentals: Sales Top\nDuring the third quarter, adjusted earnings climbed 28% to $1.75 per share and sales soared 20% to $13.15 billion. Both metrics beat forecasts.\nMerck also provided guidance following its Organon(OGN) spinoff. The pharma company boosted its full-year outlook to adjusted profit of $5.65-$5.70 per share on $47.4 billion to $47.9 billion in sales. Both measures topped expectations. And they don't include the potential for molnupiravir to gain authorizations in the U.S. or Europe.\nThe company's biggest single drug remains cancer treatment Keytruda. Keytruda accounted for more than a third of total third-quarter sales. Keytruda sales increased 22% to $4.53 billion. Sales of its human papillomavirus vaccine, Gardasil, soared 68% to $1.99 billion.\nBut revenue from diabetes med Januvia fell 1% to $1.34 billion. And Merck reported a 26% decline for its pneumonia vaccine, Pneumovax 23, as Covid vaccines took priority in the U.S.\nOverall, third-quarter metrics were in line withCAN SLIM rules for investing,which advise investors to look for companies with recent quarterly growth of 20%-25%, or better.\nIn the current quarter, analysts polled by FactSet expect Merck to earn $1.54 per share on $13.2 billion in sales. On a year-over-year basis, earnings would surge almost 22% and sales would rise north of 5%.\nWhat Do Annual Metrics Say About Merck?\nAs of the close on Nov. 30, Merck stock was down more than 4% for the year. Shares recently hit at least a three-decade high, but have since tumbled.\nLast year, Merck's sales grew 2.5% to $47.99 billion. That decelerated from 11% growth in 2019.\nFor 2021, analysts expect sales to rise a fraction to $48.49 billion. Income is projected to inch 2.7% higher to $5.81 a share. That follows 14% growth in 2020.\nThe stock ranks fifth by Composite Rating in the industry group of pharma companies. The 33-company Medical-Ethical Drugs group ranks a middling No. 95 out of 197 groups tracked by Investor's Business Daily.\nMerck Stock News: Merck Grabs Covid Deal\nMerck's molnupiravir is now authorized in the U.K. Merck will supply the U.K. with 480,000 courses of the drug, now selling under the brand name Lagevrio. Now that the FDA's advisors have recommended molnupiravir, the full agency will consider the drug.\nThe U.S. deal for 1.7 million courses is worth $1.2 billion to Merck. If successful, molnupiravir could hit the U.S. market before the end of the year.\nIn addition to Merck and Pfizer,Atea Pharmaceuticals(AVIR) and Enanta Pharmaceuticals(ENTA) working on oral Covid drugs.Roche(RHHBY) recently pulled out of its deal with Atea for the Covid antiviral.\nAnalysts say the pills could offer an easier route for non-hospitalized treatment of Covid than antibody drugs from Regeneron Pharmaceuticals(REGN),Eli Lilly(LLY) and Vir Biotechnology(VIR). Antibody drugs must be given by health care professionals.\nBut there is some concern that the way molnupiravir works could introduce mutations into the DNA of an unborn baby. So, FDA advisors waffled on whether to recommend its use for pregnant women.\nFurther, Merck and Gilead Sciences(GILD) began a Phase 2 study testing a combination of their oral HIV treatments. The drugs, known as islatravir and lenacapavir can stay in the body for a long time. This means patients can take medicine less frequently. In this case, the companies are testing a weekly dosing regimen.\nMerck also recently finished acquiring Acceleron.\nIn early March, President Joe Biden announced Merck would help Johnson & Johnson(JNJ) produce its Covid vaccine. Merck will receive $268.8 million from the Biomedical Advanced Research and Development Authority to help expand facility space to do so.\nIs Merck Stock A Buy Now?\nBased on CAN SLIM rules for investing, no, Merck stock is not a buy right now. Shares have round-tripped their earlier breakout and have triggered several sell signals.\nThere are further caveats. Both Merck's sales and earnings met CAN SLIM guidelines in the third quarter. Sales aren't expected to meet that mark in the current quarter.\nStill, big stocks like Merck can add gains without hitting massive growth streaks.","news_type":1,"symbols_score_info":{"MRK":0.9}},"isVote":1,"tweetType":1,"viewCount":1089,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":7,"subscribersOnly":false,"subscribersOnlyAccessible":false,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/603062571"}